

Applicant : BAKHUTASHVILI, Vladimir  
U.S. Serial No.: 09/928,178  
Filed : August 9, 2001  
Date : February 19, 2002  
Page : 2

**REMARKS**

Applicant intends to claim priority of U.S. Serial No. 60/224,112, filed August 9, 2000 as evidenced in applicant's Declaration and Power of Attorney attached hereto as **Exhibit A**. Accordingly, applicant maintains that there is no issue of new matters and respectfully requests the entry of this Amendment.

Applicant attaches hereto a mark-up copy of the first page of the specification as **Exhibit B**. Applicant further attached hereto a clean copy of the first page of the specification as **Exhibit C**.

If a telephone interview would be of assistance in advancing prosecution of the subject application, Applicant's undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 50-1891.

Respectfully submitted,

Albert Wai Kit Chan

Albert Wai-Kit Chan  
Registration No. 36,479  
Attorney for Applicant  
141-07 20<sup>th</sup> Ave., Suite 604  
Whitestone, New York 11357  
Tel: (718) 357-8836  
Fax: (718) 357-8552

I hereby certify that this paper is being deposited this date with the U.S. Postal Service as first class mail addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Albert Wai Kit Chan 2/19/02  
Albert Wai-Kit Chan Date  
Reg. No. 36,479



CO. OF PAPERS  
ORIGINALLY FILED

Dkt. # 627A

TECH CENTER 1600/2900

MAR 18 2002

RECEIVED

**AMNIOTIC APOPTOSIS MODULATING SUBSTANCES**

5 This application claims the benefit of United States  
patent application Serial No. 60/224,112, filed on  
August 9, 2000, the content of which is incorporated  
here into this application.

10 Throughout this application, references are made to  
various publications. Disclosures of these  
publications in their entirety are hereby  
incorporated by reference into this application to  
more fully describe the state of the art to which  
this invention pertains.

15

**FIELD OF THE INVENTION**

20 The invention(s) is directed to method(s) of  
obtaining compounds from human amniotic tissue  
and/or by synthesizing these compounds by chemical  
and genetic engineering methods known in the art  
that modulate apoptosis in animals, including  
humans, their preparation, their applications in  
human conditions for the treatment of all disease  
25 conditions and other conditions in which apoptosis  
occurs and in laboratory tests for diagnostic  
studies and other potential uses.

**BACKGROUND OF THE INVENTION**

30

**APOPTOSIS**

Apoptosis is a mode of cell death that occurs under  
normal physiological conditions. It is an active  
genetically controlled process, which removes  
35 unnecessary and damaged cells. Apoptosis enables  
living organisms to control cell numbers in tissues  
and to eliminate individual cells that jeopardize  
the living organism. It takes place in developing  
embryos and in adult organisms during physiological  
40 tissue turnover and in most pathological processes.



COPY OF PAPERS  
ORIGINALLY FILED

Dkt. # 627A

TECH CENTER 1600/2900

MAR 18 2002

RECEIVED

**AMNIOTIC APOPTOSIS MODULATING SUBSTANCES**

5 This application claims the benefit of United States  
patent application Serial No. 60/224,112, filed on  
August 9, 2000, the content of which is incorporated  
here into this application.

10 Throughout this application, references are made to  
various publications. Disclosures of these  
publications in their entireties are hereby  
incorporated by reference into this application to  
more fully describe the state of the art to which  
this invention pertains.

15

**FIELD OF THE INVENTION**

The invention(s) is directed to method(s) of  
obtaining compounds from human amniotic tissue  
20 and/or by synthesizing these compounds by chemical  
and genetic engineering methods known in the art  
that modulate apoptosis in animals, including  
humans, their preparation, their applications in  
human conditions for the treatment of all disease  
25 conditions and other conditions in which apoptosis  
occurs and in laboratory tests for diagnostic  
studies and other potential uses.

**BACKGROUND OF THE INVENTION**

30

**APOPTOSIS**

Apoptosis is a mode of cell death that occurs under  
normal physiological conditions. It is an active  
genetically controlled process, which removes  
35 unnecessary and damaged cells. Apoptosis enables  
living organisms to control cell numbers in tissues  
and to eliminate individual cells that jeopardize  
the living organism. It takes place in developing  
embryos and in adult organisms during physiological  
40 tissue turnover and in most pathological processes.